These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 24095623)
1. Vasoplegia in septic shock: do we really fight the right enemy? Sharawy N J Crit Care; 2014 Feb; 29(1):83-7. PubMed ID: 24095623 [TBL] [Abstract][Full Text] [Related]
2. Vasoplegia in septic shock (review). Gamcrlidze MM; Intskirveli NA; Vardosanidze KD; Chikhladze KhE; Goliadze LSh; Ratiani LR Georgian Med News; 2015 Feb; (239):56-62. PubMed ID: 25802451 [TBL] [Abstract][Full Text] [Related]
3. [Pathophysiological mechanisms and treatment of septic shock-induced vasoplegia]. Jeanneret S; Sanchez B; Liaudet L Rev Med Suisse; 2011 Dec; 7(321):2435-8. PubMed ID: 22279861 [TBL] [Abstract][Full Text] [Related]
4. The Story of Nitric Oxide, Sepsis and Methylene Blue: A Comprehensive Pathophysiologic Review. Saha BK; Burns SL Am J Med Sci; 2020 Oct; 360(4):329-337. PubMed ID: 32631574 [TBL] [Abstract][Full Text] [Related]
5. Vasoplegia in patients with sepsis and septic shock: pathways and mechanisms. Burgdorff AM; Bucher M; Schumann J J Int Med Res; 2018 Apr; 46(4):1303-1310. PubMed ID: 29332515 [TBL] [Abstract][Full Text] [Related]
6. [Nitric oxide--an important mediator in sepsis?]. Kirkebøen KA; Strand OA Tidsskr Nor Laegeforen; 1999 Nov; 119(27):4061-5. PubMed ID: 10613098 [TBL] [Abstract][Full Text] [Related]
7. Effects of endothelin and nitric oxide on organ injury, mesenteric ischemia, and survival in experimental models of septic shock. Iskit AB; Guc O Acta Pharmacol Sin; 2003 Oct; 24(10):953-7. PubMed ID: 14531935 [TBL] [Abstract][Full Text] [Related]
13. Cardiac vasoplegia syndrome: pathophysiology, risk factors and treatment. Omar S; Zedan A; Nugent K Am J Med Sci; 2015 Jan; 349(1):80-8. PubMed ID: 25247756 [TBL] [Abstract][Full Text] [Related]
14. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 prevents myocardial dysfunction in murine models of septic shock. Ichinose F; Buys ES; Neilan TG; Furutani EM; Morgan JG; Jassal DS; Graveline AR; Searles RJ; Lim CC; Kaneki M; Picard MH; Scherrer-Crosbie M; Janssens S; Liao R; Bloch KD Circ Res; 2007 Jan; 100(1):130-9. PubMed ID: 17138944 [TBL] [Abstract][Full Text] [Related]
15. Vasoplegia treatments: the past, the present, and the future. Levy B; Fritz C; Tahon E; Jacquot A; Auchet T; Kimmoun A Crit Care; 2018 Feb; 22(1):52. PubMed ID: 29486781 [TBL] [Abstract][Full Text] [Related]
17. Effect of methylguanidine in a model of septic shock induced by LPS. Marzocco S; Di Paola R; Ribecco MT; Sorrentino R; Domenico B; Genesio M; Pinto A; Autore G; Cuzzocrea S Free Radic Res; 2004 Nov; 38(11):1143-53. PubMed ID: 15621690 [TBL] [Abstract][Full Text] [Related]
18. Nitric oxide in sepsis-syndrome: potential treatment of septic shock by nitric oxide synthase antagonists. Ketteler M; Cetto C; Kirdorf M; Jeschke GS; Schäfer JH; Distler A Kidney Int Suppl; 1998 Feb; 64():S27-30. PubMed ID: 9475485 [TBL] [Abstract][Full Text] [Related]
19. Mechanisms of vascular hyporesponsiveness in septic shock. Kimmoun A; Ducrocq N; Levy B Curr Vasc Pharmacol; 2013 Mar; 11(2):139-49. PubMed ID: 23506493 [TBL] [Abstract][Full Text] [Related]
20. A novel treatment strategy for sepsis and septic shock based on the interactions between prostanoids, nitric oxide, and 20-hydroxyeicosatetraenoic acid. Tunctan B; Korkmaz B; Sari AN; Kacan M; Unsal D; Serin MS; Buharalioglu CK; Sahan-Firat S; Schunck WH; Falck JR; Malik KU Antiinflamm Antiallergy Agents Med Chem; 2012; 11(2):121-50. PubMed ID: 23013331 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]